AgeX Therapeutics Inc (AGE)

1.82 +0.06  +3.41% NYSE AM Nov 25, 20:00 USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
03/30/2021 Earnings AgeX Therapeutics Inc Fourth Quarter Earnings Results for 2020
11/16/2020 Earnings AgeX Therapeutics Inc Third Quarter Earnings Results for 2020
08/14/2020 Earnings AgeX Therapeutics Inc Second Quarter Earnings Results for 2020
05/14/2020 Earnings AgeX Therapeutics Inc First Quarter Earnings Results for 2020
03/30/2020 Earnings AgeX Therapeutics Inc Fourth Quarter Earnings Results for 2019
03/30/2020 Misc AgeX Therapeutics Inc Annual Report for 2019
12/30/2019 Misc AgeX Therapeutics Inc Annual General Meeting for 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.agexinc.com
  • Investor Relations URL: N/A
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: N/A
  • Next Earnings Release: Mar. 30, 2021
  • Last Earnings Release: Nov. 16, 2020
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develop innovative medicines designed to address some of the unsolved problems in aging. Its PureStem derived cell-based therapeutic candidates in development are AGEX-VASC1 and AGEX-BAT1. And iTR drug-based therapeutic candidates in development are AGEX-iTR1547 and Renelon.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.